期刊文献+

Polyphyllin I promotes cell death via suppressing UPR-mediated CHOP ubiquitination and degradation in non-small cell lung cancer 被引量:6

原文传递
导出
摘要 Polyphyllin I(PPI)purified from Polyphylla rhizomes displays puissant cytotoxicity in many kinds of cancers.Several researches investigated its anti-cancer activity.But novel mechanisms are still worth investigation.This study aimed to explore PPI-induced endoplasmic reticulum(ER)stress as well as the underlying mechanism in non-small cell lung cancer(NSCLC).Cell viability or colony-forming was detected by MTT or crystal violet respectively.Cell cycle,apoptosis,reactive oxygen species(ROS)and mitochondrial membrane potential were assessed by flow cytometry.Gene and protein levels were evaluated by q RT-PCR and immunoblotting respectively.Protein interaction was determined by immunoprecipitation or immunofluorescence assay.Gene overexpression or silencing was carried out by transient transfection with plasmids or small interfering RNAs.The Cancer Genome Atlas(TCGA)database was used for Gene Set Enrichment Analysis(GSEA),survival analysis,gene expression statistics or pathway enrichment assay.PPI inhibited the propagation of NSCLC cells,increased non-viable apoptotic cells,arrested cell cycle at G2/M phase,induced ROS levels but failed to decrease mitochondrial membrane potential.High levels of GRP78 indicates poor prognosis in NSCLC patients.PPI selectively suppressed unfolded protein response(UPR)-induced GRP78 expression,subsequently protected CHOP from GRP78-mediated ubiquitination and degradation.We demonstrated that the natural product PPI,obtained from traditional herbal medicine,deserves for further study as a valuable candidate for lead compound in the chemotherapy of NSCLC.
出处 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2021年第4期255-266,共12页 中国天然药物(英文版)
基金 the National Natural Science Foundation of China(Nos.81973524 and 81703754) the 111 Project from Ministry of Education of China and the State Administration of Foreign Export Affairs of China(B18056) the Drug Innovation Major Project(Nos.2018ZX09711-001-007and 2018ZX09735002-003) the“Double First-Class”University Project(CPU2018GF03) the special funds for Science and Technology Development under the Guidance of the Central Government(ZY20198020)。
  • 相关文献

参考文献1

二级参考文献115

  • 1Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics. 2012;13:789-802.
  • 2Siegel R, NaBhadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
  • 3Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res. 2013;1:2.
  • 4Dziadziuszko R, Jassem J. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Ann Oncol. 2012;23:x193-6.
  • 5Heuckmann JM, Rauh D, Thomas RK Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol. 2012;30:3417-20.
  • 6Rossi A. Cetuximab and non-small-cell lung cancer: end of the story? Lancet Oncok 2013;14:1251-3.
  • 7Berger C, Madshus IH, Stang E. Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. Exp Cell Res. 2012;318:2578-91.
  • 8Sareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007;18:vi35-41.
  • 9Passaro A, Alesini D, Pochesci A, Cortesi E. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. Anticancer Agents Med Chem. 2014;14:646-50.
  • 10Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Curr Oncol Rep. 2014;16:390.

共引文献9

同被引文献75

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部